Hims & Hers Health (NYSE:HIMS) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Hims & Hers from "sell" to "hold", and analysts overall give the stock an average "Hold" rating (3 Buys, 13 Holds, 1 Sell) with a mean price target of $31.71.
• Recent quarter: the company beat EPS expectations ($0.08 vs. $0.02), delivered revenue up 28.4% YoY but slightly under consensus, and the stock trades around $19.45 with a $4.43B market cap and a PE of 38.14.
• Insider selling was significant in mid‑March (COO sold 97,289 shares), with insiders selling 129,889 shares (~$3.23M) over 90 days, while institutions/hedge funds own about 63.5% of the stock.

Hims & Hers Health (NYSE:HIMS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

Several other research analysts also recently weighed in on HIMS. Evercore set a $24.00 price target on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Bank of America upgraded shares of Hims & Hers Health from an "underperform" rating to a "neutral" rating and increased their price target for the stock from $12.50 to $23.00 in a research report on Tuesday, March 10th. TD Cowen decreased their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating on the stock in a research report on Friday, March 27th. Needham & Company LLC upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 price target on the stock in a research report on Monday, March 9th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $31.71.

Hims & Hers Health Stock Down 1.5%

HIMS opened at $19.45 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a market capitalization of $4.43 billion, a PE ratio of 38.14, a PEG ratio of 1.88 and a beta of 2.32. The firm's 50 day simple moving average is $19.72 and its two-hundred day simple moving average is $33.55.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same period last year, the firm earned $0.11 earnings per share. The company's quarterly revenue was up 28.4% on a year-over-year basis. As a group, equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 5,529 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares of the company's stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Chi sold 97,289 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the transaction, the chief operating officer directly owned 407,282 shares of the company's stock, valued at $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 129,889 shares of company stock valued at $3,230,986. Insiders own 13.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC grew its stake in shares of Hims & Hers Health by 427.1% in the 4th quarter. Hsbc Holdings PLC now owns 33,582 shares of the company's stock worth $1,090,000 after buying an additional 27,211 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Hims & Hers Health by 13.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company's stock worth $1,334,000 after buying an additional 4,980 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new position in shares of Hims & Hers Health in the 4th quarter worth $80,000. SHP Wealth Management purchased a new position in shares of Hims & Hers Health in the 4th quarter worth $106,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Hims & Hers Health by 413.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company's stock worth $559,000 after buying an additional 13,873 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.